Menter, A., Blauvelt, A., Strober, B., Colombo, M., Kisa, R., Kundu, S., Banerjee, S. and Leonardi, C. (2020) “Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis”, SKIN The Journal of Cutaneous Medicine, 4(6), p. s72. doi: 10.25251/skin.4.supp.72.